Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Glioma, Malignant
Open-data reference.
20 US clinical trials · 14 currently recruiting
Active & Recent Trials
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
Northwell Health
NCT05271240
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Tango Therapeutics
NCT06810544
Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma
Darell Bigner
NCT04547777
Imaging of Solid Tumors Using 18F-TRX
Rahul Aggarwal
NCT06942104
Safety and Tolerability of Fb-PMT in Recurrent Glioblastoma
NanoPharmaceuticals
NCT05226494
Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma
Northwell Health
NCT05954858
Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG
Children's Hospital of Philadelphia
NCT05555550
18F-Fluciclovine PET-MRI in High-grade Glioma
Children's Hospital of Philadelphia
NCT05553041
PrOton Pulsed reduCed dOse Rate Radiotherapy for Recurrent CNS maligNancies Trial
Baptist Health South Florida
NCT06397560
Window of Opportunity Study of DSP-0390 in Gliomas
Washington University School of Medicine
NCT06636162
Repeated Neural Stem Cell Based Virotherapy for Newly Diagnosed High Grade Glioma
Northwestern University
NCT06169280
CUE-102 in Recurrent Glioblastoma
David Reardon, MD
NCT06917885
Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG
Nader Sanai
NCT05773326
Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)
Northwell Health
NCT05979064
AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients
Nader Sanai
NCT05182905
Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma
Nader Sanai
NCT05076513
ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM
Mustafa Khasraw, MBChB, MD, FRCP, FRACP
NCT05283109
Niraparib In Recurrent IDH 1/2 Gliomas
Massachusetts General Hospital
NCT05406700
Temporally-modulated Pulsed Radiation Therapy (TMPRT) After Prior EBRT for Recurrent IDH-mutant Gliomas
Washington University School of Medicine
NCT05393258
Effect of Perampanel on Peritumoral Hyperexcitability in HGG
Dana-Farber Cancer Institute
NCT04497142
Phase Distribution
| Phase | Trial count |
|---|---|
| Early Phase 1 | 15 |
| Phase 3 | 1 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the Glioma, Malignant Trial Landscape
ClinicalTrials.gov lists 20 US studies indexed under Glioma, Malignant, and 14 of those are currently open to recruitment — roughly 70% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
The phase distribution for Glioma, Malignant shows 1 late-stage studies (Phase 3 and Phase 4 combined) alongside 15 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
Top sponsor activity for Glioma, Malignant is led by Nader Sanai with 3 indexed trials, alongside 9 other organizations in the top contributor list. The list on this page surfaces up to 20 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for Glioma, Malignant?
PlainTrial tracks 20 US clinical trials for Glioma, Malignant, of which 14 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Glioma, Malignant?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2024 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.